0001735276-24-000022.txt : 20240301
0001735276-24-000022.hdr.sgml : 20240301
20240301161255
ACCESSION NUMBER: 0001735276-24-000022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHARP PHILLIP A
CENTRAL INDEX KEY: 0001226295
ORGANIZATION NAME:
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 24709843
MAIL ADDRESS:
STREET 1: BIOGEN INC LEGAL DEPARTMENT
STREET 2: 14 CAMBRIDGE CENTER
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER NAME:
FORMER CONFORMED NAME: SHARP PHILIP A
DATE OF NAME CHANGE: 20030407
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-29
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001226295
SHARP PHILLIP A
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE
MA
02142
1
0
0
0
1
Common Stock
2024-02-29
4
M
0
30000
59.25
A
30000
D
Common Stock
2024-02-29
4
S
0
13005
150.6
D
16995
D
Common Stock
2024-02-29
4
S
0
13557
151.43
D
3438
D
Common Stock
2024-02-29
4
S
0
915
152.4
D
2523
D
Common Stock
2024-02-29
4
S
0
1906
153.62
D
617
D
Common Stock
2024-02-29
4
S
0
101
154.07
D
516
D
Common Stock
2024-02-29
4
S
0
516
156.54
D
0
D
Common Stock
266899
I
by Trust
Stock Option (right to buy)
59.25
2024-02-29
4
M
0
30000
0.0
D
2015-06-05
2024-06-04
Common Stock
30000
0
D
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2023. The 30,000 options exercised and sold by the reporting person were due to expire on June 4, 2024.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $150.00 to $151.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $151.01 to $151.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $152.02 to $152.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.04 to $154.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.06 to $154.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $156.15 to $156.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
By: Stephen Hall, Attorney-in-Fact For: Phillip A. Sharp
2024-03-01